Background: Rivaroxaban is a directly acting, oral anti-coagulant (factor Xa inhibitor) which is used to treat and prevent the formation of blood clots. A common side effect of this drug is an increase in bleeding tendencies, which can potentially lead to macroscopic hematuria. However, it is important to note that macroscopic hematuria can appear in several other conditions including urological malignancies. The Case: We report a case of a 69-year-old male patient with a history of myocardial infarction undergoing long term Rivaroxaban therapy, presenting with macroscopic hematuria and frequent urination. The clinical history and presenting symptoms were consistent with the side effects of prolonged use of Rivaroxaban, but further investigations revealed the presence of a tumor in the bladder which was instead found to be the cause of macroscopic hematuria. The conclusion: Although macroscopic hematuria is a very common side effect of Rivaroxaban therapy, it is important to consider other conditions which can present with the same symptoms.
References
[1]
Singh, R. and Emmady, P.D. (2023) Rivaroxaban. https://www.ncbi.nlm.nih.gov/books/NBK557502/
[2]
Beyer-Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., et al. (2014) Rates, Management, and Outcome of Rivaroxaban Bleeding in Daily Care: Results from the Dresden NOAC Registry. Blood, 124, 955-962. https://doi.org/10.1182/blood-2014-03-563577
[3]
Fujino, Y., Takahashi, C., Mitsumoto, K. and Uzu, T. (2019) Rivaroxaban-Related Acute Kidney Injury in a Patient with Iga Vasculitis. BMJ Case Reports, 12, e227756. https://doi.org/10.1136/bcr-2018-227756
[4]
Seryozhev Mladenov, B., Mariyanovski, V. and Hadzhiyska, V. (2015) Macroscopic Hematuria in Patients on Anticoagulation Therapy. Central European Journal of Urology, 68, 330-333. https://doi.org/10.5173/ceju.2015.658
[5]
Seryozhev Mladenov, B., Mariyanovski, V. and Hadzhiyska, V. (2015) Macroscopic Hematuria in Patients on Anticoagulation Therapy. Central European Journal of Urology, 68, 330-333. https://doi.org/10.5173/ceju.2015.658
[6]
Hicks, D. and Li, C.Y. (2007) Management of Macroscopic Haematuria in the Emergency Department. Emergency Medicine Journal, 24, 385-390.
[7]
Jakus, D., Šolić, I., Jurić, I., Borovac, J.A. and Šitum, M. (2023) The Impact of the Initial Clinical Presentation of Bladder Cancer on Histopathological and Morphological Tumor Characteristics. Journal of Clinical Medicine, 12, Article No. 4259. https://doi.org/10.3390/jcm12134259
[8]
Bolenz, C., Schröppel, B., Eisenhardt, A., Schmitz-Dräger, B.J. and Grimm, M. (2018) The Investigation of Hematuria. DeutschesÄrzteblatt international, 115, 801-807. https://doi.org/10.3238/arztebl.2018.0801
[9]
Wallis, C.J.D., Juvet, T., Lee, Y., Matta, R., Herschorn, S., Kodama, R., et al. (2017) Association between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA, 318, 1260-1271. https://doi.org/10.1001/jama.2017.13890
[10]
Dobruch, J. and Oszczudłowski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina, 57, Article No. 749. https://doi.org/10.3390/medicina57080749
[11]
Antoniewicz, A.A., Zapała, Ł., Poletajew, S. and Borówka, A. (2012) Macroscopic Hematuria—A Leading Urological Problem in Patients on Anticoagulant Therapy: Is the Common Diagnostic Standard Still Advisable? ISRN Urology, 2012, Article ID: 710734. https://doi.org/10.5402/2012/710734
[12]
Burger, M., Catto, J.W.F., Dalbagni, G., Grossman, H.B., Herr, H., Karakiewicz, P., et al. (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63, 234-241. https://doi.org/10.1016/j.eururo.2012.07.033
[13]
Kirkali, Z., Chan, T., Manoharan, M., Algaba, F., Busch, C., Cheng, L., et al. (2005) Bladder Cancer: Epidemiology, Staging and Grading, and Diagnosis. Urology, 66, 4-34. https://doi.org/10.1016/j.urology.2005.07.062
[14]
Jeong, S. and Ku, J.H. (2022) Urinary Markers for Bladder Cancer Diagnosis and Monitoring. Frontiers in Cell and Developmental Biology, 10, Article ID: 892067. https://doi.org/10.3389/fcell.2022.892067